Lung Adenocarcinoma Stage IV
2 clinical trials · Condition
◉ Watch Lung Adenocarcinoma Stage IV
| Record | Firm | Date |
|---|---|---|
| Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma (NCT05503667) | Shanghai Pulmonary Hospital, Shanghai, China | 2022-02-01 |
| Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma (NCT04310943) | Zhou Chengzhi | 2021-03-01 |
Track Lung Adenocarcinoma Stage IV automatically
Every clearance here is in the API, with alerts when new ones post.